• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
Conclusions: This meta-analysis revealed that PD is associated with an increase of CRP levels. CRP might be a risk factor for PD or PD leads to an inflammatory response. Introduction Parkinson's disease (PD) is one of the most complex neuro-degenerative disorders next to Alzheimer's disease. It is characterized by bradykinesia, tremor, rigidity, abnormal postural, and gait (1). PD has been recognized by the selective loss of dopaminergic neurons within the substantia nigra pars compacta, whereas the exact etiology remains elusive (2). Previously, multiple inferences have reviewed the environmental a...
Source: Frontiers in Neurology - April 16, 2019 Category: Neurology Source Type: research

Sensory Re-weighting for Postural Control in Parkinson ’s Disease
In this study, we focused primarily on the change of sensory weighting parameters when sensory conditions change. We also tested the additional hypothesis that levodopa medication would improve sensory weighting for postural control. Materials and Methods Subjects The Institutional Review Board at Oregon Health and Science University (OHSU) approved the protocol for this experiment, and all subjects gave informed consent prior to participating. Eight subjects with PD (three female) and eight healthy, age-matched controls (two female) were recruited from the Balance Disorders Laboratory database and the Parkinson’...
Source: Frontiers in Human Neuroscience - April 16, 2019 Category: Neuroscience Source Type: research

Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone
ABSTRACT The controlled trial Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) reported an unexpected increase in acute myocardial infarction (AMI) with entacapone use in patients with Parkinson's disease (PD). The authors investigated whether entacapone increased cardiovascular and mortality risk compared with the use of a non‐levodopa dopamine agonist (DA) or a selective monoamine oxidase type‐B inhibitor (MAOBI). Using national Medicare data, a new‐user cohort of elderly patients with PD treated with entacapone was propensity score (PS) matched with new users of either DA or MAOBI. T...
Source: Movement Disorders - February 26, 2013 Category: Neurology Authors: David J. Graham, James R. Williams, Ya‐Hui Hsueh, Katlyn Calia, Mark Levenson, Simone P. Pinheiro, Thomas E. MaCurdy, David Shih, Chris Worrall, Jeffrey A. Kelman Tags: Research Article Source Type: research